ProShare Advisors LLC Acquires 433 Shares of Teleflex Incorporated (NYSE:TFX)

ProShare Advisors LLC increased its holdings in shares of Teleflex Incorporated (NYSE:TFX) by 3.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,633 shares of the medical technology company’s stock after purchasing an additional 433 shares during the period. ProShare Advisors LLC’s holdings in Teleflex were worth $2,657,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. US Bancorp DE boosted its holdings in shares of Teleflex by 69.7% in the 4th quarter. US Bancorp DE now owns 11,884 shares of the medical technology company’s stock valued at $2,963,000 after acquiring an additional 4,881 shares during the last quarter. Advisory Services Network LLC purchased a new stake in Teleflex in the fourth quarter valued at $176,000. Nomura Asset Management Co. Ltd. grew its position in Teleflex by 9.3% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 12,397 shares of the medical technology company’s stock worth $3,091,000 after purchasing an additional 1,055 shares during the period. Hsbc Holdings PLC grew its position in Teleflex by 13.3% during the 4th quarter. Hsbc Holdings PLC now owns 83,474 shares of the medical technology company’s stock worth $20,795,000 after purchasing an additional 9,807 shares during the period. Finally, Allianz Asset Management GmbH raised its stake in shares of Teleflex by 38.6% during the 4th quarter. Allianz Asset Management GmbH now owns 8,503 shares of the medical technology company’s stock valued at $2,120,000 after buying an additional 2,370 shares during the last quarter. 95.62% of the stock is currently owned by institutional investors.

Teleflex Stock Up 0.8 %

Shares of NYSE:TFX opened at $246.83 on Friday. The company has a market capitalization of $11.63 billion, a price-to-earnings ratio of 39.62, a PEG ratio of 2.23 and a beta of 1.16. Teleflex Incorporated has a 12-month low of $177.63 and a 12-month high of $257.85. The business has a 50-day moving average price of $236.98 and a 200 day moving average price of $221.08. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, August 1st. The medical technology company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.33 by $0.09. Teleflex had a net margin of 8.76% and a return on equity of 14.51%. The firm had revenue of $749.70 million for the quarter, compared to analyst estimates of $762.98 million. During the same period in the prior year, the business posted $3.41 EPS. The business’s revenue for the quarter was up .9% compared to the same quarter last year. Sell-side analysts expect that Teleflex Incorporated will post 13.97 EPS for the current year.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Thursday, August 15th were paid a $0.34 dividend. The ex-dividend date was Thursday, August 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.55%. Teleflex’s payout ratio is presently 21.83%.

Insider Activity at Teleflex

In related news, Director Stuart A. Randle sold 2,674 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $238.93, for a total transaction of $638,898.82. Following the completion of the transaction, the director now directly owns 5,496 shares in the company, valued at approximately $1,313,159.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.43% of the company’s stock.

Wall Street Analyst Weigh In

TFX has been the topic of several recent research reports. Truist Financial upped their price objective on Teleflex from $240.00 to $247.00 and gave the stock a “hold” rating in a research report on Monday, August 5th. Royal Bank of Canada upped their price objective on shares of Teleflex from $235.00 to $260.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and raised their target price for the company from $205.00 to $245.00 in a research report on Monday, July 1st. Finally, Stephens increased their price target on Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $265.57.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.